Patents by Inventor Christof M. Niemeyer

Christof M. Niemeyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150064713
    Abstract: Methods, kits and systems for determining whether a reaction occurs between a chimeric transmembrane receptor and an intracellular interaction partner thereof within a cell.
    Type: Application
    Filed: September 3, 2013
    Publication date: March 5, 2015
    Inventors: Philippe Bastiaens, Stephanie Reisewitz, Giuseppe Arrabito, Leif Dehmelt, Silke Gandor, Hendrik Schroeder, Christof M. Niemeyer
  • Publication number: 20100255558
    Abstract: The invention relates to supramolecular bioconjugates and to methods for assembling and utilizing supramolecular bioconjugates. Supramolecular bioconjugates comprise a plurality of first nucleic acids and a plurality of mediators wherein each mediator comprises a second nucleic acid complementary to a sequence within said plurality of first nucleic acids. To assemble a supramolecular bioconjugate, one or more sets of bioreactive agents are coupled to the plurality of mediators, forming a plurality of bioreactive complexes. The plurality of bioreactive complexes are hybridized to the plurality of first nucleic acids to form the supramolecular bioconjugate. Bioconjugates can be used to detect and isolate targets, to screen samples for targets such as antigens, to treat patients with multiple agents or to diagnose disorders in the form of a kit.
    Type: Application
    Filed: May 5, 2009
    Publication date: October 7, 2010
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Christof M. Niemeyer, Charles R. Cantor, Takeshi Sano, Cassandra L. Smith
  • Patent number: 7569341
    Abstract: The invention relates to supramolecular bioconjugates and to methods for assembling and utilizing supramolecular bioconjugates. Supramolecular bioconjugates comprise a plurality of first nucleic acids and a plurality of mediators wherein each mediator comprises a second nucleic acid complementary to a sequence within said plurality of first nucleic acids. To assemble a supramolecular bioconjugate, one or more sets of bioreactive agents are coupled to the plurality of mediators, forming a plurality of bioreactive complexes The plurality of bioreactive complexes are hybridized to the plurality of first nucleic acids to form the supramolecular bioconjugate. Bioconjugates can be used to detect and isolate targets, to screen samples for targets such as antigens, to treat patients with multiple agents or to diagnose disorders in the form of a kit.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: August 4, 2009
    Assignee: Trustees of Boston University
    Inventors: Christof M. Niemeyer, Charles R. Cantor, Takeshi Sano, Cassandra L. Smith
  • Publication number: 20040009500
    Abstract: Items described herein possess an activated surface for immobilisation of bioorganic macromolecules, i.e.
    Type: Application
    Filed: January 31, 2003
    Publication date: January 15, 2004
    Applicant: chimera biotec GmbH
    Inventors: Rudiger Benters, Christof M. Niemeyer, Dieter Wohrle
  • Publication number: 20030118595
    Abstract: The invention relates to supramolecular bioconjugates and to methods for assembling and utilizing supramolecular bioconjuigates. Supramolecalar bioconjugates comprise a plurality of first nucleic acids and a plurality of mediators wherein each mediator comprises a second nucleic acid complementary to a sequence within said plurality of first nucleic acids. To assemble a supramolecalar bioconjugate, one or more sets of bioreactive agents are coupled to the plurality of mediators, forming a plurality of bioreactive complexes The plurality of bioreactive complexes are hybridized to the plurality of first nucleic acids to form the supramolecular bioconjugate. Bioconjugates can be used to detect and isolate targets, to screen samples for targets such as antigens, to treat patients with multiple agents or to diagnose disorders in the form of a kit.
    Type: Application
    Filed: November 7, 1997
    Publication date: June 26, 2003
    Inventors: CHRISTOF M. NIEMEYER, CHARLES R. CANTOR, TAKESHI SANO, CASSANDRA L. SMITH
  • Patent number: 5965133
    Abstract: The invention is directed to constructs and compositions containing multimeric forms of nucleic acid. Multimeric nucleic acids comprise single-stranded nucleic acids attached via biotin to streptavidin and bound with a functional group. These constructs can be utilized in vivo to treat or identify diseased tissue or cells. Repeated administrations of multimeric nucleic acid compositions produce a rapid and specific amplification of nucleic acid constructs and their attached functional groups. For treatment purposes, functional groups may be toxins, radioisotopes, genes or enzymes. Diagnostically, labeled multimeric constructs may be used to identify specific targets in vivo or in vitro. Multimeric nucleic acids may also be used in nanotechnology and to create self-assembling polymeric aggregates such as membranes of defined porosity, microcircuits and many other products.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: October 12, 1999
    Assignees: Trustees of Boston University, Univ. of Mass. Medical Center
    Inventors: Charles R. Cantor, Christof M. Niemeyer, Cassandra L. Smith, Takeshi Sano, Donald J. Hnatowich, Mary Rusckowski
  • Patent number: 5561043
    Abstract: The invention is directed to constructs and compositions containing multimeric forms of nucleic acid. Multimeric nucleic acids comprise single-stranded nucleic acids attached via biotin to streptavidin and bound with a functional group. These constructs can be utilized in vivo to treat or identify diseased tissue or cells. Repeated administrations of multimeric nucleic acid compositions produce a rapid and specific amplification of nucleic acid constructs and their attached functional groups. For treatment purposes, functional groups may be toxins, radioisotopes, genes or enzymes. Diagnostically, labeled multimeric constructs may be used to identify specific targets in vivo or in vitro. Multimeric nucleic acids may also be used in nanotechnology and to create self-assembling polymeric aggregates such as membranes of defined porosity, microcircuits and many other products.
    Type: Grant
    Filed: January 31, 1994
    Date of Patent: October 1, 1996
    Assignee: Trustees of Boston University
    Inventors: Charles R. Cantor, Christof M. Niemeyer, Cassandra L. Smith, Takeshi Sano, Donald J. Hnatowich, Mary Rusckowski